News Highlights: Top Equities Stories of the Day
October 24 2016 - 11:30PM
Dow Jones News
IBM in Talks With Australia On Settlement Over Bungled Census
International Business Machines Corp. is negotiating a
settlement with Australia's government over a bungled effort to
oversee the country's first online census, senior executives said
Tuesday. (published 0227 GMT)
Kyushu Railway Shares Soar 20% Over IPO Price in Tokyo Debut
Kyushu Railway Co. made its debut on the Tokyo Stock Exchange
Tuesday as its shares climbed 20% against the initial public
offering price in the first 15 minutes of trading. (published 0123
GMT)
GOME Electrical Appliances: Expects January-September Net Profit to Fall 70%-80% on Year
GOME Electrical Appliances Holding Ltd., an electrical appliance
retailer in China and Hong Kong, said late Monday it expects its
net profit for the January-September period to fall 70%-80% from a
year earlier, due to the implementation of a transformation plan to
improve its retail strategy. (published 0149 GMT)
Mapletree Industrial Trust 2Q Distribution Per Unit 2.83 Singapore Cents
Mapletree Industrial Trust Tuesday said its fiscal-second
quarter distribution per unit rose 1.4%, helped mainly by a rise in
rentals. (published 0117 GMT)
Belle International Interim Net Profit Down 20% on Year
Shoe retailer Belle International Holdings Ltd. late Monday
reported a 20% drop in its interim net profit, partly dragged down
by weaker same store sales and increased cost of sale. (published
0113 GMT)
Quam Expects April-Sept Results to Worsen Significantly From Year Earlier
Financial services company Quam Ltd. said late Monday it expects
its April-September financial results to worsen significantly from
a year earlier due to weak market sentiment. (published 0054
GMT)
CapitaLand Retail China Trust: 3Q Distribution Per Unit 2.36 Singapore Cents, Down 11% On Year
CapitaLand Retail China Trust, a Singapore-based real estate
investment trust, said Tuesday that its third-quarter distribution
per unit dropped 11% from a year earlier to 2.36 Singapore cents,
due to weaker net property income. (published 0045 GMT)
Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
Merck & Co.'s immunotherapy cancer drug Keytruda received
U.S. Food and Drug Administration approval as a first-line
treatment for certain lung cancer patients. (published 0020
GMT)
(END) Dow Jones Newswires
October 24, 2016 23:15 ET (03:15 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.